Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Clin Ophthalmol ; 12: 2399-2407, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30538423

RESUMO

BACKGROUND: Lack of efficacy due to bad compliance caused by intolerance issues is the main reason for a change to a better tolerated ocular treatment, such as using preservative-free (PF) eye drops. AIM: To assess the efficacy and local tolerance after 12 months and patient satisfaction regarding local treatment tolerance and handling at inclusion and after 6 months of PF latanoprost compared to preserved glaucoma eye drops. METHODS: This was an international, prospective, and observational real-life study. Up to three visits, one at inclusion and two follow-up visits (one after 6 and one after 12 months) were planned. Efficacy, local tolerance, and patient satisfaction were the main evaluation criteria. RESULTS: Data from 721 patients were available for the statistical analysis. Overall, 64.8% (467/721) of patients switched treatment before inclusion: 62.2% in the preserved and 68.9% in the PF latanoprost group. IOP values were similar between PF latanoprost and preserved eye drops and remained stable at all visits. Ocular signs and symptoms improved after switching to PF latanoprost; the prevalence of conjunctival hyperemia was significantly lower (P=0.0015) at both follow-up visits. At follow-up visit 1, 49.5% of the patients who switched to PF latanoprost decreased or stopped the use of artificial tears. Satisfaction regarding tolerance in patients using PF latanoprost improved significantly after the switch from preserved eye drops to PF latanoprost (88.9% and 42.5%, respectively, P<0.0001). CONCLUSION: This first real-life study showed that PF latanoprost was as efficacious but better tolerated than preserved eye drops over a sustained period of 12 months, while providing a significantly higher patient satisfaction and potentially allowing improvement in the patient's daily life.

2.
Tidsskr Nor Laegeforen ; 137(17)2017 Sep 19.
Artigo em Norueguês | MEDLINE | ID: mdl-28925204
3.
J Clin Microbiol ; 40(7): 2668-770, 2002 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-12089304

RESUMO

Moraxella nonliquefaciens, a commensal organism of the upper respiratory tract, is generally considered to have low pathogenic potential. We report here two cases of severe endophthalmitis occurring 9 years and 2 months after glaucoma filtration surgery, respectively. Apart from sulfonamide, very low MICs were recorded for several antibiotics tested. Identification was based on phenotypic characteristics in combination with sequencing of the 16S rRNA gene.


Assuntos
Endoftalmite/etiologia , Moraxella/patogenicidade , Infecções por Neisseriaceae/etiologia , Trabeculectomia/efeitos adversos , Idoso , DNA Bacteriano/genética , Farmacorresistência Bacteriana , Genes Bacterianos , Humanos , Masculino , Dados de Sequência Molecular , Moraxella/efeitos dos fármacos , Moraxella/genética , Moraxella/isolamento & purificação , RNA Bacteriano/genética , RNA Ribossômico 16S/genética , Infecção da Ferida Cirúrgica/etiologia , Fatores de Tempo , Virulência
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA